Enlivex (ENLV) Cash & Current Investments (2013 - 2025)
Enlivex (ENLV) posted quarterly Cash & Current Investments of $5.8 million for Q4 2025, down 75.51% year-over-year from $23.5 million in Q4 2024, and up 130.0% quarter-over-quarter from -$19.2 million in Q3 2025.
Enlivex (ENLV) Cash & Current Investments (2013 - 2025) Analysis & Trends
Enlivex's Cash & Current Investments history runs 13 years deep, the most recent figure standing at $5.8 million for Q4 2025.
- In Q4 2025, Cash & Current Investments fell 75.51% year-over-year to $5.8 million; the TTM figure through Dec 2025 stood at $5.8 million (down 75.51% YoY), while the FY2025 annual figure was $5.8 million, up 119.8% from the prior year.
- Cash & Current Investments for Q4 2025 stood at $5.8 million, up from -$19.2 million in the prior quarter.
- The five-year high for Cash & Current Investments was $78.0 million in Q1 2022, with the low at -$30.8 million in Q2 2023.
- The 5-year median for Cash & Current Investments is $22.8 million (2021), against an average of $22.4 million.
- Peak annual rise in Cash & Current Investments reached 378.43% in 2023, while the deepest fall reached 149.04% in 2023.
- Enlivex's Cash & Current Investments stood at $69.9 million in 2021, then plunged by 83.79% to $11.3 million in 2022, then soared by 378.43% to $54.2 million in 2023, then tumbled by 56.68% to $23.5 million in 2024, then sank by 75.51% to $5.8 million in 2025.
- Business Quant data shows ENLV's Cash & Current Investments at $5.8 million in Q4 2025, -$19.2 million in Q3 2025, and $19.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | 5.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.76 Mn |
| Sep 30, 2025 | -19.19 Mn |
| Jun 30, 2025 | 19.51 Mn |
| Mar 31, 2025 | 20.55 Mn |
| Dec 31, 2024 | 23.50 Mn |
| Sep 30, 2024 | -28.45 Mn |
| Jun 30, 2024 | 25.94 Mn |
| Mar 31, 2024 | 23.44 Mn |
| Dec 31, 2023 | 54.24 Mn |
| Sep 30, 2023 | -28.27 Mn |
| Jun 30, 2023 | -30.76 Mn |
| Mar 31, 2023 | -18.05 Mn |
| Dec 31, 2022 | 11.34 Mn |
| Sep 30, 2022 | 57.66 Mn |
| Jun 30, 2022 | 62.88 Mn |
| Mar 31, 2022 | 78.00 Mn |
| Dec 31, 2021 | 69.94 Mn |
| Sep 30, 2021 | 22.15 Mn |
| Jun 30, 2021 | 23.61 Mn |
| Mar 31, 2021 | 73.23 Mn |